These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

158 related articles for article (PubMed ID: 37153058)

  • 21. The Synergistic Use of IL-15 and IL-21 for the Generation of NK Cells From CD3/CD19-Depleted Grafts Improves Their
    Heinze A; Grebe B; Bremm M; Huenecke S; Munir TA; Graafen L; Frueh JT; Merker M; Rettinger E; Soerensen J; Klingebiel T; Bader P; Ullrich E; Cappel C
    Front Immunol; 2019; 10():2816. PubMed ID: 31849984
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Ex vivo expanded allogeneic natural killer cells have potent cytolytic activity against cancer cells through different receptor-ligand interactions.
    Jung D; Baek YS; Lee IJ; Kim KY; Jang H; Hwang S; Jung J; Moon YW; Park KS; Choi YS; An HJ
    J Exp Clin Cancer Res; 2021 Oct; 40(1):333. PubMed ID: 34686187
    [TBL] [Abstract][Full Text] [Related]  

  • 23. TLR8 stimulation enhances cetuximab-mediated natural killer cell lysis of head and neck cancer cells and dendritic cell cross-priming of EGFR-specific CD8+ T cells.
    Stephenson RM; Lim CM; Matthews M; Dietsch G; Hershberg R; Ferris RL
    Cancer Immunol Immunother; 2013 Aug; 62(8):1347-57. PubMed ID: 23685782
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Cytotoxic effects of ex vivo-expanded natural killer cell-enriched lymphocytes (MYJ1633) against liver cancer.
    Choi JW; Lee ES; Kim SY; Park SI; Oh S; Kang JH; Ryu HA; Lee S
    BMC Cancer; 2019 Aug; 19(1):817. PubMed ID: 31426763
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Synergistic cytotoxicity of ex vivo expanded natural killer cells in combination with monoclonal antibody drugs against cancer cells.
    Deng X; Terunuma H; Nieda M; Xiao W; Nicol A
    Int Immunopharmacol; 2012 Dec; 14(4):593-605. PubMed ID: 23063974
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Umbilical cord mesenchymal stem cells increase expansion of cord blood natural killer cells.
    Boissel L; Tuncer HH; Betancur M; Wolfberg A; Klingemann H
    Biol Blood Marrow Transplant; 2008 Sep; 14(9):1031-1038. PubMed ID: 18721766
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Radiotherapy enhances natural killer cell cytotoxicity and localization in pre-clinical canine sarcomas and first-in-dog clinical trial.
    Canter RJ; Grossenbacher SK; Foltz JA; Sturgill IR; Park JS; Luna JI; Kent MS; Culp WTN; Chen M; Modiano JF; Monjazeb AM; Lee DA; Murphy WJ
    J Immunother Cancer; 2017 Dec; 5(1):98. PubMed ID: 29254507
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Fully automated expansion and activation of clinical-grade natural killer cells for adoptive immunotherapy.
    Granzin M; Soltenborn S; Müller S; Kollet J; Berg M; Cerwenka A; Childs RW; Huppert V
    Cytotherapy; 2015 May; 17(5):621-32. PubMed ID: 25881519
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Increased proliferation, lytic activity, and purity of human natural killer cells cocultured with mitogen-activated feeder cells.
    Rabinowich H; Sedlmayr P; Herberman RB; Whiteside TL
    Cell Immunol; 1991 Jul; 135(2):454-70. PubMed ID: 1709827
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Optimization of Large-Scale Expansion and Cryopreservation of Human Natural Killer Cells for Anti-Tumor Therapy.
    Min B; Choi H; Her JH; Jung MY; Kim HJ; Jung MY; Lee EK; Cho SY; Hwang YK; Shin EC
    Immune Netw; 2018 Aug; 18(4):e31. PubMed ID: 30181919
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Cetuximab intensifies the ADCC activity of adoptive NK cells in a nude mouse colorectal cancer xenograft model.
    Chen S; Li X; Chen R; Yin M; Zheng Q
    Oncol Lett; 2016 Sep; 12(3):1868-1876. PubMed ID: 27602116
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Ex vivo expansion of highly cytotoxic human NK cells by cocultivation with irradiated tumor cells for adoptive immunotherapy.
    Lim SA; Kim TJ; Lee JE; Sonn CH; Kim K; Kim J; Choi JG; Choi IK; Yun CO; Kim JH; Yee C; Kumar V; Lee KM
    Cancer Res; 2013 Apr; 73(8):2598-607. PubMed ID: 23580577
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Effects of ADAM10 and ADAM17 Inhibitors on Natural Killer Cell Expansion and Antibody-dependent Cellular Cytotoxicity Against Breast Cancer Cells
    Pham DH; Kim JS; Kim SK; Shin DJ; Uong NT; Hyun H; Yoon MS; Kang SJ; Ryu YJ; Cho JS; Yoon JH; Lee JS; Cho D; Lee SH; Park MH
    Anticancer Res; 2017 Oct; 37(10):5507-5513. PubMed ID: 28982863
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Carfilzomib combined with ex vivo-expanded patient autologous natural killer cells for myeloma immunotherapy.
    Chang SK; Hou J; Chen GG; Yu DD; Wu HQ; Xie YS; Hu LN; Gao L; Xiao WQ; Kong YY; Tao Y; Shi JM
    Neoplasma; 2018 Sep; 65(5):720-729. PubMed ID: 29940772
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Autologous Natural Killer Cell-enrichment for Immune Cell Therapy: Preclinical Setting Phase, Shiraz Experience.
    Rezaeifard S; Heike Y; Masuyama JI; Rezvani A; Vojdani R; Erfani N
    Iran J Allergy Asthma Immunol; 2021 Apr; 20(2):233-243. PubMed ID: 33904681
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Expansion of Human NK Cells Using K562 Cells Expressing OX40 Ligand and Short Exposure to IL-21.
    Kweon S; Phan MT; Chun S; Yu H; Kim J; Kim S; Lee J; Ali AK; Lee SH; Kim SK; Doh J; Cho D
    Front Immunol; 2019; 10():879. PubMed ID: 31105701
    [No Abstract]   [Full Text] [Related]  

  • 37. Canine non-B, non-T NK lymphocytes have a potential antibody-dependent cellular cytotoxicity function against antibody-coated tumor cells.
    Kim Y; Lee SH; Kim CJ; Lee JJ; Yu D; Ahn S; Shin DJ; Kim SK
    BMC Vet Res; 2019 Oct; 15(1):339. PubMed ID: 31610784
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Expansion of natural killer cells with lytic activity against autologous blasts from adult and pediatric acute lymphoid leukemia patients in complete hematologic remission.
    Torelli GF; Guarini A; Maggio R; Alfieri C; Vitale A; Foà R
    Haematologica; 2005 Jun; 90(6):785-92. PubMed ID: 15951291
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Phenotypic and Functional Dysregulated Blood NK Cells in Colorectal Cancer Patients Can Be Activated by Cetuximab Plus IL-2 or IL-15.
    Rocca YS; Roberti MP; Juliá EP; Pampena MB; Bruno L; Rivero S; Huertas E; Sánchez Loria F; Pairola A; Caignard A; Mordoh J; Levy EM
    Front Immunol; 2016; 7():413. PubMed ID: 27777574
    [TBL] [Abstract][Full Text] [Related]  

  • 40.
    Veluchamy JP; Lopez-Lastra S; Spanholtz J; Bohme F; Kok N; Heideman DA; Verheul HM; Di Santo JP; de Gruijl TD; van der Vliet HJ
    Front Immunol; 2017; 8():87. PubMed ID: 28220124
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.